Wedbush Maintains Outperform on Longboard Pharmaceuticals, Raises Price Target to $44
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Laura Chico maintains an Outperform rating on Longboard Pharmaceuticals and raises the price target from $40 to $44.
September 17, 2024 | 12:27 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Wedbush analyst Laura Chico has increased the price target for Longboard Pharmaceuticals from $40 to $44 while maintaining an Outperform rating. This suggests a positive outlook for the company's stock.
The increase in price target from $40 to $44 by a reputable analyst suggests confidence in Longboard Pharmaceuticals' future performance. The Outperform rating indicates that the stock is expected to do better than the market average, which is likely to positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100